retatrutide regulatory approval The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, October 27, 2025: U.K. regulators

GLP-1 medications are powerful tools for weight loss, and with the right strategy, they can help you achieve long-term health goals while feeling your best

International researchers examined Swedish health records of almost 95,000 people with a diagnosis of depression or anxiety who were also taking various diabetes medications between 2009 and 2022

According to our latest data, 44% of UK users have a new go-to retailer for groceries and household essentials

Results Feedback forms from 115 remote (n=68) and in-person (n=47) interviews lasting 90-minutes (n=77) or 30-75-minutes (n=38) with patients (n=98) and caregivers (n=17) from the US (n=80), Germany (n=13), Japan (n=11) and China (n=11) across various indications/diseases (e.g

Specialist consultation included

Retatrutide is the first triple hormone receptor agonist (GIP, GLP-1, glucagon) to reach Phase 3 clinical trials